

AMERISOURCEBERGEN CORP  
Form 8-K  
August 01, 2012

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, DC 20549

---

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

---

Date of Report (Date of earliest event reported): **July 31, 2012**

**AmerisourceBergen Corporation**

(Exact name of Registrant as specified in its charter)

**Delaware**  
(State or Other

**1-16671**  
Commission File Number

**23-3079390**  
(I.R.S. Employer

Jurisdiction of

Identification

Incorporation or

Number)

Organization)

---

Edgar Filing: AMERISOURCEBERGEN CORP - Form 8-K

**1300 Morris Drive**

**Chesterbrook, PA**

(Address of principal executive offices)

**19087**

(Zip Code)

Registrant's telephone number, including area code: **(610) 727-7000**

**N/A**

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

- ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  - ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
  - ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
  - ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-

Item 8.01. Other Events.

On July 31, 2012, AmerisourceBergen Corporation (the Registrant ) issued a news release announcing that the Registrant had signed a three year agreement to supply approximately \$18.5 billion in pharmaceuticals to Express Scripts on an annual basis. The agreement is effective October 1, 2012.

The contract is expected to contribute approximately 23 percent of the Registrant's revenues, and about 3 percent of its earnings per share. The contract award has no impact on the Registrant's expectations for fiscal 2012 or on its preliminary expectations for fiscal 2013, which the Registrant previously disclosed in a news release issued on July 26, 2012.

A copy of the news release is furnished as Exhibit 99.1 to this report and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

99.1 News Release, dated July 31, 2012, of AmerisourceBergen Corporation, regarding Registrant's three year pharmaceutical supply agreement with Express Scripts.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMERISOURCEBERGEN CORPORATION

Date: August 1, 2012

By: /s/ Tim G. Guttman

Name:

Tim G. Guttman

Title:

Senior Vice President and Chief Financial  
Officer